Business
IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
POTOMAC, MD / ACCESS Newswire / September 2, 2025 /IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in Alzheimer's dementia, to ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in Alzheimer's dementia, to a new international site at Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada.","length":362,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":624,"height":369,"url":"https://media.zenfs.com/en/accesswire.ca/8b1e7366aaf0b22564e26fbf9cd54643"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2Eq4NwMYHoKXgQaK.rTklg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/8b1e7366aaf0b22564e26fbf9cd54643","width":624,"height":369}}},{"type":"text","content":""Bringing CALMA to Canada is a milestone in our mission to offer innovative solutions for individuals living with Alzheimer's disease," said Ram Mukunda, CEO of IGC Pharma. "This expansion reflects the CALMA trial's continued growth across North America, broadening access to diverse patient populations and reinforcing IGC's commitment to advancing IGC-AD1 through a robust, multi-site clinical program. We are honored to collaborate with the experienced team at Island Health to reach more families affected by this condition."","length":561,"tagName":"p"},{"type":"text","content":"This marks the CALMA trial's continued growth across North America, aiming to increase access for patients and caregivers affected by Alzheimer's disease and its neuropsychiatric symptoms. The addition of Royal Jubilee Hospital strengthens the trial's clinical infrastructure and supports timely enrollment as the Company works toward trial completion.","length":364,"tagName":"p"},{"type":"text","content":"The CALMA Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of IGC-AD1 in managing agitation in patients with Alzheimer's disease, a symptom that significantly impacts quality of life and care outcomes.","length":269,"tagName":"p"},{"type":"text","content":"Island Health's Clinical Trials Unit at Royal Jubilee Hospital is now actively involved...